STELLA PHARMA CORPORATION (4888) AI Stock Analysis

• Market Cap: ¥12.35B
• Dividend Yield: N/A
• Average Volume (3M): 156.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: 268.05%
• EPS Growth: 83.57%
• Country: JP
• Employees: 44
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -4.60
• Shares Outstanding: 34,034,100
• 10 Day Avg. Volume: 118,020
• 30 Day Avg. Volume: 156,550
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥424.00
• Price Target Upside: 16.80% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: ¥403.00 ▲(11.02% Upside)

The overall stock score of 50 reflects a balance between strong revenue growth and a solid equity base against the backdrop of ongoing operational losses and negative profit margins. Technical indicators suggest a lack of strong momentum, while valuation metrics highlight the company's current lack of profitability. The absence of earnings call insights and corporate events means these factors did not influence the score.

STELLA PHARMA CORPORATION Business Overview & Revenue Model

Company Description

Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.

How the Company Makes Money

STELLA PHARMA CORPORATION makes money through the sale of its pharmaceutical products, particularly in the oncology space. The company's revenue model primarily relies on the development and commercialization of proprietary drugs that are sold to healthcare providers, hospitals, and clinics. Revenue streams are bolstered by partnerships with other pharmaceutical companies and research institutions, which can include licensing agreements, joint ventures, and collaborative research projects. Additionally, the company may generate income from royalties on licensed technologies and products as well as government grants for research and development in therapeutic areas.

STELLA PHARMA CORPORATION Financial Statement Overview

Summary

STELLA PHARMA CORPORATION has shown strong revenue growth and a solid equity base, indicating potential for future growth. However, persistent operational losses and negative profit margins are concerning. The transition to positive free cash flow is a positive sign, suggesting potential for improved financial health.

Income Statement

The company has shown significant revenue growth over the years, with a remarkable increase from ¥100 million in 2022 to ¥961 million in 2025. However, the company is not profitable yet, as it continues to report negative net income and EBIT. Profit margins are negative, which is a concern as it indicates ongoing operational challenges.

Balance Sheet

The balance sheet shows a strong equity position with Stockholders' Equity consistently higher than Total Debt, resulting in a low Debt-to-Equity ratio. The equity ratio is robust, reflecting a stable financial structure. However, the presence of high net losses could affect future equity levels if not addressed.

Cash Flow

The company has improved its cash flow position, transitioning from negative free cash flow in earlier years to positive free cash flow in 2025. Operating cash flow has also turned positive, which is a positive sign for operational efficiency. However, the ratio of operating cash flow to net income is low due to significant net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	961.57M	961.06M	269.49M	229.07M	100.10M	205.97M
Gross Profit	825.76M	811.03M	217.49M	206.94M	84.86M	181.78M
EBITDA	-99.06M	-99.06M	-723.85M	-738.34M	-726.86M	-621.70M
Net Income	-140.94M	-140.81M	-763.75M	-778.82M	-767.72M	-659.24M
Balance Sheet
Total Assets	5.42B	5.42B	3.82B	4.33B	4.72B	2.05B
Cash, Cash Equivalents and Short-Term Investments	3.21B	3.21B	2.35B	2.71B	3.28B	1.25B
Total Debt	766.78M	766.78M	933.30M	1.09B	1.25B	1.41B
Total Liabilities	2.21B	2.21B	1.44B	1.58B	1.64B	1.82B
Stockholders Equity	3.21B	3.21B	2.38B	2.75B	3.08B	230.72M
Cash Flow
Free Cash Flow	0.00	136.50M	-887.82M	-857.00M	-1.13B	-795.25M
Operating Cash Flow	0.00	140.41M	-876.84M	-827.67M	-1.08B	-772.81M
Investing Cash Flow	0.00	287.58M	-9.01M	-29.93M	-350.56M	-22.86M
Financing Cash Flow	0.00	721.25M	228.35M	291.82M	3.83B	-332.40M

STELLA PHARMA CORPORATION Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 363.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4888, the sentiment is Negative. The current price of 363 is below the 20-day moving average (MA) of 374.90, below the 50-day MA of 397.98, and below the 200-day MA of 415.31, indicating a bearish trend. The MACD of -12.88 indicates Positive momentum. The RSI at 41.89 is Neutral, neither overbought nor oversold. The STOCH value of 61.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4888.

STELLA PHARMA CORPORATION Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4880	66 Neutral	¥11.48B	-229.22	3.94%	0.86%	-13.81%	-107.95%
4888	50 Neutral	¥12.35B	―	―	―	268.05%	83.57%
4583	48 Neutral	¥9.12B	-8.55	―	―	30.92%	26.00%
4579	47 Neutral	¥14.19B	-24.80	-8.37%	―	40.66%	24.86%
4599	47 Neutral	¥18.83B	-9.73	―	―	―	5.59%
4588	41 Neutral	¥15.95B	-6.68	-61.22%	―	-9.04%	2.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%